Guardant Health Raises Full-Year Revenue Guidance to $1.32B on Robust Q1 Results
GH has more than doubled off its 52-week low of $36.36.
Summary
Guardant Health reported strong first-quarter 2026 revenue of $301.7 million, a 48% year-over-year increase, driven by significant growth in oncology and screening test volumes. Crucially, the company raised its full-year 2026 revenue guidance to a range of $1.30–$1.32 billion, up from previous estimates. This positive financial update follows the recent FDA approval of its Guardant360® Cdx liquid biopsy, indicating strong operational momentum. The raised guidance signals management's increased confidence in future performance and is a material positive catalyst for the stock, likely to be viewed favorably by investors. Traders will monitor continued growth in test adoption and further commercial expansion initiatives.
At the time of this announcement, GH was trading at $94.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $36.36 to $120.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.